News

The challenge: to reduce the dose without an increase in patient-reported pain intensity.

An alternative to opioids is shown to be effective in patients with diabetic neuropathy, complex regional pain syndrome, and failed spine surgery.

The committee recommends the approval of baricitinib 2-mg, but not 4-mg; this comes a year after baricitinib was rejected by the FDA.

Recent studies have shed light on the pathophysiology, clinical diagnosis, and effective management of fibromyalgia. Are you up-to-date?

Researchers analyzed mortality statistics from the CDC to determine the relative burden of SLE-related deaths among women.

The American College of Rheumatology developed a formal curriculum for NPs and PAs to help swell the ranks of clinicians who provide rheumatologic care.

Researchers look deep to find the cause of synovitis and dactylitis in patients with psoriatic arthritis.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

RF positive, young with high disease activity . . . a big negative for MTX success.

Do statins increase or lower the risk of rheumatoid arthritis? Researchers sorted through a host of confounding factors to arrive at an answer.

For better or worse, social media and the Internet have a large role in the lives of young people-and as such are an effective way to reach them.

Female athletes face a higher risk of requiring additional knee surgery.

A study sheds new light on the extra-articular manifestations of spondyloarthritis-with a focus on the heart as a high-risk target.

Upadacitinib (15 mg, once-daily) met both primary endpoints, with 71% of patients achieving ACR20 and 29% achieving clinical remission at week 12.

This morning, AbbVie revealed positive top-line results from the Phase 3 SELECT-COMPARE clinical trial evaluating upadacitinib in rheumatoid arthritis.

A potential alternative to immunosuppressants for the treatment of joint inflammation in lupus.

The time to revisit treatment approaches for gout is now.

Which patients need bisphosphonate therapy-and for how long?

These strategies address critical issues that have stymied the lupus drug development process for decades.

However, researchers found that a common treatment for SLE reduces the risk of flares to that of non-pregnant women with lupus.

Although the screening controversy has been smoldering for some time, a recent article may have added fuel to the fire.

Consider screening for systemic lupus erythematosus in young patients who exhibit an escalating pattern of health care utilization.

Bariatric surgery can result in bone as well as weight loss.

This heart-healthy diet may help prevent osteoporosis and fractures in postmenopausal women.

Are you up-to-date on the latest recommendations for PsA from EULAR and GRAPPA? Take our 6-question quiz to find out.

This novel interleukin-23 inhibitor targets psoriatic inflammation.

Vitamin D deficiency can compromise bone strength and increase susceptibility to severe fracture.

Despite its antioxidant properties, uric acid may not be as neuroprotective as previously thought.

Are you prepared to recognize and treat anxiety, depression, and other comorbid psychiatric disorders when they arise in your patients?

Recent findings call into question the safety of long-term febuxostat therapy in patients with cardiovascular disease.